Premium
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
Author(s) -
Kawamura M.,
Ohara S.,
Koike T.,
Iijima K.,
Suzuki J.,
Kayaba S.,
Noguchi K.,
Hamada S.,
Noguchi M.,
Shimosegawa T.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2003.01539.x
Subject(s) - lansoprazole , cyp2c19 , gastroenterology , medicine , reflux , helicobacter pylori , genotype , omeprazole , proton pump inhibitor , pepsin , biology , biochemistry , enzyme , disease , cytochrome p450 , metabolism , gene
Summary Background : The acid suppressive effect of lansoprazole is influenced by the P450 2C19 (CYP2C19) polymorphism. Aim : To investigate whether the CYP2C19 genotype is related to the healing of erosive reflux oesophagitis during treatment with lansoprazole. Methods : Eighty‐eight Japanese patients with erosive reflux oesophagitis were treated with a daily oral dose of 30 mg lansoprazole for 8 weeks. The CYP2C19 genotype, Helicobacter pylori infection status and serum pepsinogen I/II ratio were assessed before treatment. At 4 and 8 weeks, the healing of erosive reflux oesophagitis was evaluated endoscopically. Results : The healing rates were 57.1%, 69.2% and 72.7% at 4 weeks and 77.4%, 95.0% and 100% at 8 weeks in homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers, respectively. At 8 weeks, the healing rate of erosive reflux oesophagitis was significantly lower in homozygous extensive metabolizers than in the other two groups ( P < 0.05). The H. pylori status and serum pepsinogen I/II ratio had less influence than CYP2C19 polymorphism on the healing rate of erosive reflux oesophagitis. Conclusions : The therapeutic effect of lansoprazole on erosive reflux oesophagitis is influenced by the CYP2C19 genotype status. Therefore, a test of CYP2C19 genotype may be useful for the medical treatment of reflux oesophagitis with lansoprazole.